I suspect that was the EAP trial that finished some years ago. The data from that was presented to the ODAC, including the step change after Mesoblast took over the trial. When the EAP started it was under the auspices of Osiris, why I searched for prochymal at the time.
https://clinicaltrials.gov/ct2/show/NCT00759018?term=prochymal&cond=Graft-versus-host-disease
Based on very occasional comments from Silviu I believe Mesoblast continued to supply remestemcel-L for quite some time after the EAP finished, like years. Definitely worth confirmation of what is happening now.
I also did some comparison of the footprint remestemcel-L had across the US hospital system through various trials, seemed to be about 43 institutions.
MSB Trading 2021 - paradigm shift, page-3886
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.020(1.78%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.19 | $1.14 | $5.245M | 4.520M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 160275 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 17174 | 9 |
View Market Depth
| Last trade - 12.33pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.020 ( 2.91 %) |
||||
| Open | High | Low | Volume | ||
| $1.16 | $1.19 | $1.14 | 585920 | ||
| Last updated 12.54pm 22/05/2024 ? | |||||
| MSB (ASX) Chart |